An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab for Prolonging Bone Metastasis-Free Survival in Men with Hormone-Refractory Prostate Cancer
- Registry ID
- EUCTR2010-021846-23
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE3
- Sponsor
- Amgen Inc
- Start date
- 2010-08-20
- Completion date
- 2014-02-21
- Last update
- 2026-08-16
Conditions
- Castrate-resistant prostate cancer
Summary
To describe the safety and tolerability of denosumab administration as measured by adverse events, immunogenicity, and safety laboratory parameters in subjects who previously received denosumab
Locations
View on source registry